- Drugmakers Merck and Moderna announced that an experimental mRNA cancer therapy named intismeran successfully prevented melanoma from returning or spreading.
- The personalized treatment was administered in combination with the cancer drug Keytruda to patients who had surgery to remove their melanoma.
- Moderna CEO Stéphane Bancel described the Phase 3 trial findings as a pivotal moment for the field of cancer research.
- Melanoma is the deadliest form of skin cancer, with over 8,500 deaths and 112,000 new diagnoses expected in the United States this year.
- Detailed results showing how long patients lived without disease progression will be presented at an upcoming medical conference later this year.
IN FULL
